These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 38145448

  • 1. Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer.
    Jin LL, Lu HJ, Shao JK, Wang Y, Lu SP, Huang BF, Hu GN, Jin HC, Wang CQ.
    Mol Cell Biochem; 2024 Nov; 479(11):3037-3047. PubMed ID: 38145448
    [Abstract] [Full Text] [Related]

  • 2. EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Wang CQ, Li Y, Huang BF, Zhao YM, Yuan H, Guo D, Su CM, Hu GN, Wang Q, Long T, Wang Y, Tang CH, Li X.
    Sci Rep; 2017 Nov 15; 7(1):15654. PubMed ID: 29142206
    [Abstract] [Full Text] [Related]

  • 3. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY, Liu YN, Wu SG, Hsu CL, Chang TH, Tsai MF, Lin YT, Shih JY.
    Cancer Biomark; 2020 Nov 15; 28(3):351-363. PubMed ID: 32417760
    [Abstract] [Full Text] [Related]

  • 4. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL.
    Breast Cancer Res; 2012 Jul 12; 14(4):R104. PubMed ID: 22788954
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B.
    Breast Cancer Res; 2019 Jul 01; 21(1):77. PubMed ID: 31262335
    [Abstract] [Full Text] [Related]

  • 7. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2.
    Jia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S, Cheng K, Zou W.
    Gene; 2016 Nov 15; 593(1):41-47. PubMed ID: 27506313
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M, Yang J, Lv W, Wang S, Du T, Zhang K, Wu Y, Feng X.
    Biosci Rep; 2022 Jan 28; 42(1):. PubMed ID: 34935899
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-145 inhibits migration and invasion via inhibition of fascin 1 protein expression in non-small-cell lung cancer cells.
    Zhang Y, Yang X, Wu H, Zhou W, Liu Z.
    Mol Med Rep; 2015 Oct 28; 12(4):6193-8. PubMed ID: 26238532
    [Abstract] [Full Text] [Related]

  • 11. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
    Li Q, Zhang D, Chen X, He L, Li T, Xu X, Li M.
    Sci Rep; 2015 Nov 06; 5():16082. PubMed ID: 26542452
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3.
    Sharma U, Barwal TS, Khandelwal A, Malhotra A, Rana MK, Singh Rana AP, Imyanitov EN, Vasquez KM, Jain A.
    Biochimie; 2021 Mar 06; 182():99-107. PubMed ID: 33429003
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
    Wang LL, Huang WW, Huang J, Huang RF, Li NN, Hong Y, Chen ML, Wu F, Liu J.
    Kaohsiung J Med Sci; 2020 Aug 06; 36(8):581-591. PubMed ID: 32311203
    [Abstract] [Full Text] [Related]

  • 17. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D, Jia H, Zhang Z, Li S.
    Bioorg Chem; 2021 Apr 06; 109():104722. PubMed ID: 33618253
    [Abstract] [Full Text] [Related]

  • 18. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
    Yang Y, Wang W, Chang H, Han Z, Yu X, Zhang T.
    J Cell Mol Med; 2019 Nov 06; 23(11):7331-7341. PubMed ID: 31507089
    [Abstract] [Full Text] [Related]

  • 19. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
    Chen F, Luo N, Hu Y, Li X, Zhang K.
    Cell Physiol Biochem; 2018 Nov 06; 47(5):2147-2158. PubMed ID: 29975921
    [Abstract] [Full Text] [Related]

  • 20. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
    BMC Cancer; 2020 Dec 04; 20(1):1189. PubMed ID: 33276757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.